Co-staining with specific tumor-infiltrating lymphocyte marker and anti-Nrf2 antibodies maybe used in future studies to address the role of Nrf2 expression in activation of lymphocyte trafficking. The gene discussed is NFE2L2; the disease is neoplasm.